CURE’s Top Stories: March 2021

Article

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for March 2021.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for March 2021.

5. Is Delaying Cancer Screening Due to COVID-19 Fears Worth the Risk?

Postponing tests or doctor visits during the pandemic may increase the risk of cancer. In this story from our Women’s Cancers Special Issue, we take a look at the experiences of several women who had to alter their cancer screening plans as a result of COVID-19.

4. ‘Flat’ Women are Reshaping the Fashion World

Body image and body positivity are very important, especially after a life-changing surgery such as a mastectomy, writes a breast cancer survivor. Here, she offers fashion suggestions to help “flatties” to feel their best.

3. Johnson & Johnson’s Single-Dose COVID-19 Vaccine a ‘Tremendous Asset’ for Patients With Cancer

The Food and Drug Administration’s recent emergency use authorization of Johnson & Johnson’s single-dose COVID-19 vaccine will likely open many doors for patients with cancer to get vaccinated. In this interview, Dr. Katherine Mullin of the Roswell Park Comprehensive Cancer Center recommends that patients with cancer get whichever vaccine is available at the time they go to get vaccinated.

2. A New Way to Fight Triple-Negative Breast Cancer Arrives

Even as chemotherapy, surgery and radiation remain treatment mainstays, immunotherapy is ready to take the stage in the fight against triple-negative breast cancer. Learn more about it in this story.

1. A Non-Small Cell Lung Cancer Survivor Shares Her Story

In our top story of the month, a young mother and athlete discusses receiving a shocking diagnosis of stage 4 lung cancer and her incredible response to treatment with a single, targeted drug.

Thank you for reading!

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Jennifer King from the GO2 Foundation for Lung Cancer in an interview with CURE